^(131)I-rituximab对B细胞淋巴瘤细胞生物学效应的实验研究

Biological response of B-cell lymphoma cells in vitro to ^(131)I-rituximab

目的研究131I标记的rituximab对CD20高表达的B细胞淋巴瘤细胞的生物学效应,为放射免疫导向治疗提供实验依据。方法 IODO-GEN法将131I标记于抗CD20单抗rituximab,用Annexin Ⅴ-FITC／PI双染法检测131I-rituximab对 Raji细胞的诱导凋亡作用,PI染色法检测细胞周期分布。结果 Annexin Ⅴ-FITC／PI双染法检测凋亡率:131I-rituximab组凋亡率为51．99％,131I组为42．71％,rituximab组为29．42％,对照组为26．17％。对照组和rituximab组凋亡率明显低于131I 组和131I-rituximab组(P<0．05)。PI染色法对比各组的凋亡率(亚二倍体峰):131I-rituximab组细胞凋亡率为4．32％,131I组为 1．47％,rituximab组为1．39％,对照组仅0．37％,131I-rituximab组凋亡率明显高于其他各组(P<0．05)。131I-rituximab组Raji细胞周期发生变化,细胞大部分被阻滞于G1／G2期。结论 131I-rituximab能够调控Raji细胞的细胞周期并诱导其凋亡,从而抑制Raji细胞增殖。

Objective To study the biological response of B-cell lymphoma cells positive for CD20 expression to t3q-labeled rituximab. Methods Anti-CD20 monoclonal antibody rituximab was labeled with ^131Ⅰ by means of IODO-GEN method, and its effects on apoptosis of Raji cells were determined by Annexin-V/PI double-labeled cytometry. Its effects on the cell cycles was evaluated by cytometry With PI staining. Results The cell apoptosis rate measured by Annexin V-FITC/PI was 51.99% in^131Ⅰ-rituximab group, significantly higher than that in ^131Ⅰ group, rituximab group and control group （42,71%, 29.42% and 26.17%, respectively, P〈0.05）. The apoptosis rate by flow cytometry with PI staining was 4.32% in ^131Ⅰ-rituximab group, also significantly higher than that in the other 3 groups （1.47%, 1.39% and 0.37%, respectively, P〈0.05）. Cell cycle alteration of Raji cells occurred in ^131Ⅰ-rituximab group, and the majority of cells were arrested at G1/G2 stage. Conclusion ^131Ⅰ-rituximab can regulate the cell cycle of Raji cells and induce their apoptosis to inhibit their proliferation.